CTNM on Nasdaq
Contineum Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
-$60.0MNet income, fiscal 20252
Compare with Semnur Pharmaceuticals, Inc., Lexicon Pharmaceuticals or Gossamer Bio, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $51.5M | $38.4M |
| General and administrative | $16.5M | $12.5M |
| Total operating expenses | $68.1M | $50.9M |
| Loss from operations | -$68.1M | -$50.9M |
| Interest income | $8.2M | $8.9M |
| Change in fair value of warrant liability | $0 | -$106.0K |
| Other expense, net | -$165.0K | -$163.0K |
| Total other income, net | $8.1M | $8.6M |
| Net loss | -$60.0M | -$42.3M |
| Unrealized gain on marketable securities | $189.0K | -$37.0K |
| Comprehensive loss | -$59.8M | -$42.3M |
| Net loss per share, basic (in dollars per share) | -$2.17 | -$2.18 |
| Net loss per share, diluted (in dollars per share) | -$2.17 | -$2.18 |
| Weighted-average shares of common shares outstanding, basic (in shares) | 27.7M shares | 19.4M shares |
| Weighted-average shares of common shares outstanding, diluted (in shares) | 27.7M shares | 19.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2024-09-30 | 2024-03-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $75.6M | $21.9M | |||
| Marketable securities | $187.3M | $182.8M | |||
| Prepaid expenses and other current assets | $5.0M | $1.6M | |||
| Total current assets | $267.9M | $206.4M | |||
| Property and equipment, net | $830.0K | $989.0K | |||
| Other long-term assets | $256.0K | $3.0K | |||
| Operating lease right-of-use assets | $7.6M | $1.9M | $5.5M | $5.6M | |
| Total assets | $276.6M | $212.8M | |||
| Accounts payable | $1.0M | $1.8M | |||
| Accrued expenses | $6.4M | $6.7M | |||
| Current portion of operating lease liabilities | $2.3M | $1.5M | |||
| Total current liabilities | $9.7M | $10.0M | |||
| Operating lease liabilities, net of current portion | $5.9M | $4.8M | |||
| Total liabilities | $15.7M | $14.8M | |||
| Preferred stock, $0.001 par value; authorized shares10,000,000 at December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | |||
| Additional paid-in-capital | $438.1M | $315.4M | |||
| Accumulated deficit | -$177.4M | -$117.4M | |||
| Accumulated other comprehensive income | $260.0K | $71.0K | |||
| Total stockholders equity | $261.0M | $198.1M | |||
| Total liabilities and stockholders equity | $276.6M | $212.8M | |||
| Common stock, shares authorized (in shares) | 220.0M shares | ||||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2024-09-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $75.6M | $21.9M | ||||
| Marketable securities | $187.3M | $182.8M | ||||
| Prepaid expenses and other current assets | $5.0M | $1.6M | ||||
| Total current assets | $267.9M | $206.4M | ||||
| Property and equipment, net | $830.0K | $989.0K | ||||
| Other long-term assets | $256.0K | $3.0K | ||||
| Operating lease right-of-use assets | $7.6M | $1.9M | $5.5M | $5.6M | ||
| Total assets | $276.6M | $212.8M | ||||
| Accounts payable | $1.0M | $1.8M | ||||
| Accrued expenses | $6.4M | $6.7M | ||||
| Current portion of operating lease liabilities | $2.3M | $1.5M | ||||
| Total current liabilities | $9.7M | $10.0M | ||||
| Operating lease liabilities, net of current portion | $5.9M | $4.8M | ||||
| Total liabilities | $15.7M | $14.8M | ||||
| Preferred stock, $0.001 par value; authorized shares10,000,000 at December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||||
| Additional paid-in-capital | $438.1M | $315.4M | ||||
| Accumulated deficit | -$177.4M | -$117.4M | ||||
| Accumulated other comprehensive income | $260.0K | $71.0K | ||||
| Total stockholders equity | $261.0M | $198.1M | -$67.9M | |||
| Total liabilities and stockholders equity | $276.6M | $212.8M | ||||
| Common stock, shares authorized (in shares) | 220.0M shares | |||||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | 10.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$60.0M | -$42.3M |
| Depreciation and amortization | $323.0K | $258.0K |
| Non-cash operating lease expense | $1.1M | $872.0K |
| Stock-based compensation | $10.0M | $6.8M |
| Accretion of premiums/discounts on marketable securities, net | -$791.0K | -$3.9M |
| Loss (gain) on sale of property and equipment | $67.0K | -$16.0K |
| Change in fair value of warrant liability | $0 | $106.0K |
| Gain on marketable securities | -$12.0K | -$5.0K |
| Prepaid expenses and other current assets | -$3.4M | $887.0K |
| Other long-term assets | $3.0K | $937.0K |
| Accounts payable | -$869.0K | $1.1M |
| Accrued expenses | -$516.0K | $2.3M |
| Operating lease liabilities | -$1.3M | $66.0K |
| Net cash used in operating activities | -$55.3M | -$32.8M |
| Purchase of property and equipment | -$231.0K | -$514.0K |
| Proceeds from sale of equipment | $0 | $20.0K |
| Purchases of marketable securities | -$162.5M | -$226.4M |
| Sales and maturities of marketable securities | $159.0M | $157.2M |
| Net cash used in investing activities | -$3.7M | -$69.7M |
| Payments of deferred offering costs | -$256.0K | $0 |
| Proceeds from exercise of stock options | $219.0K | $405.0K |
| Proceeds from employee stock purchase plan | $467.0K | $385.0K |
| Net cash provided by financing activities | $112.7M | $109.0M |
| Net increase in cash and cash equivalents | $53.7M | $6.4M |
| Property and equipment purchases included in accounts payable | $0 | $58.0K |
| Reclassification of warrants from liability to equity | $0 | $216.0K |
| Reclassification of deferred offering costs paid in prior year to equity | $0 | $343.0K |
| Right-of-use assets obtained in exchange for lease liabilities | $3.3M | $5.6M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Contineum Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerCarmine N. Stengone Apr 4, 2024 to now8
- PresidentCarmine N. Stengone Apr 4, 2024 to now8
- Chief financial officerPeter T. Slover Apr 4, 2024 to now9
Board members and other officers (11)
- CMO & Head of DevelopmentTim Watkins Apr 28, 2025 to now10
- Chief Scientific OfficerDaniel S. Lorrain Apr 4, 2024 to now11
- CMO & Sr VP, Clinical Dev.Stephen L. Huhn Apr 4, 2024 to Jan 31, 202512
- Board memberGines Diego Miralles Mar 17, 2025 to now13
- Board memberCarmine N. Stengone Apr 4, 2024 to now8
- Board memberEvert B. Schimmelpennink Apr 4, 2024 to now14
- Board memberOlivia C. Ware Apr 4, 2024 to now15
- Board memberTodd R. Brady Apr 4, 2024 to now16
- Board memberTroy A. Ignelzi May 20, 2024 to now17
- Board memberSarah Boyce Jun 24, 2024 to now18
- General counselJohn Stephen Healy Jun 3, 2024 to now19
Timeline
- Apr 4, 2024New chief executive Carmine N. Stengone becomes CEO8
Filings
194 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 27 major events, 78 insider forms, 22 large holders, 57 other. The latest 20:
- Oct 1, 2026144 EDGAR
- Sep 14, 20268-K EDGAR
- Sep 8, 2026144 EDGAR
- Sep 8, 20264 EDGAR
- Sep 1, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 3, 2026144 EDGAR
- Aug 3, 2026144 EDGAR
- Aug 3, 20264 EDGAR
- Jul 30, 202610-Q EDGAR
- Jul 30, 20268-K EDGAR
- Jul 27, 2026SCHEDULE 13G EDGAR
- Jul 17, 2026SCHEDULE 13G/A EDGAR
- Jul 13, 20268-K EDGAR
- Jul 10, 20264 EDGAR
- Jul 8, 2026144 EDGAR
- Jul 8, 20264 EDGAR
- Jul 2, 20264 EDGAR
- Jul 1, 2026144 EDGAR
- Jul 1, 20264 EDGAR
The 194 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 22 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Jul 27, 2026SCHEDULE 13G
- Jul 17, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- Apr 17, 2026SCHEDULE 13G
- Feb 17, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G
- Feb 17, 2026SCHEDULE 13G
- Jan 29, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Montanova Capital, LLC | 2,841,334 | $46.6M | 1.0% | No change |
| Jupiter Topco LLC | 2,734,836 | $44.8M | 0.0% | New |
| BlackRock, Inc. | 2,064,345 | $33.8M | 0.0% | +1,395,222 |
| Johnson & Johnson | 1,979,173 | $32.4M | 4.1% | No change |
| Franklin Resources Inc | 1,839,227 | $30.1M | 0.0% | No change |
| Balyasny Asset Management L.P. | 1,522,793 | $25.0M | 0.0% | −162,842 |
| Vanguard Capital Management LLC | 1,321,356 | $21.7M | 0.0% | +107,183 |
| Perceptive Advisors LLC | 1,255,592 | $20.6M | 0.3% | No change |
| Fmr LLC | 1,040,130 | $17.0M | 0.0% | +225,259 |
| Millennium Management LLC | 931,709 | $15.3M | 0.0% | −603,740 |
| Great Point Partners LLC | 921,481 | $15.1M | 3.6% | +121,283 |
| Longaeva Partners L.P. | 812,757 | $13.3M | 0.4% | +80,669 |
| Ikarian Capital, LLC | 807,874 | $13.2M | 2.2% | No change |
| Sectoral Asset Management Inc | 727,587 | $11.9M | 8.3% | No change |
| Geode Capital Management, LLC | 693,188 | $11.4M | 0.0% | +411,150 |
| Hhlr Advisors, Ltd. | 669,337 | $11.0M | 1.3% | No change |
| Red Tree Management, LLC | 638,158 | $10.5M | 7.1% | No change |
| Versant Venture Management, LLC | 542,628 | $8.9M | 5.5% | No change |
| Goldman Sachs Group Inc | 497,255 | $8.2M | 0.0% | +190,147 |
| Boxer Capital Management, LLC | 494,000 | $8.1M | 0.6% | No change |
| State Street Corp | 425,902 | $7.0M | 0.0% | +324,624 |
| Citadel Advisors LLC | 396,354 | $6.5M | 0.0% | +46,154 |
| Adage Capital Partners Gp, L.l.c. | 328,000 | $5.4M | 0.0% | New |
| Silverarc Capital Management, LLC | 296,135 | $4.9M | 0.5% | −5,594 |
| ADAR1 Capital Management, LLC | 278,961 | $4.6M | 0.2% | +2,300 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARGines Diego Miralles, Board member
- 14
- 15SEC EDGAROlivia C. Ware, Board member
- 16SEC EDGARTodd R. Brady, Board member
- 17SEC EDGARTroy A. Ignelzi, Board member
- 18SEC EDGARSarah Boyce, Board member
- 19SEC EDGARJohn Stephen Healy, General counsel